Written by Peter G. Traber, M.D. on July 31, 2015

During the normal course of conducting business in a public company like Galectin Therapeutics, as the CEO and Chief Medical Officer of the company, I have conversations and interactions with many different firms and individuals on a daily basis. I am frequently discussing and fielding questions on science, our drug development programs, and many other topics from investors, analysts, scientists, physicians and others. At all times, the factual information that is discussed during these conversations has been previously publically disclosed and is available in our filings with the U.S. Securities and Exchange Commission. Everyone has access to all the information that I, or any other employee of the Company, discloses to individuals outside of the company.

In a highly technical area such as drug development, our investors and other interested members of the public have a great thirst for information and explanation of our programs I would like to help investors and members of the public understand our programs and answer questions that I routinely hear using a new communication medium that we designed, called “CEO Perspectives”. In this series of “CEO Perspectives” I will address key areas of activities for Galectin informed by questions that I receive from various constituents. It is my hope that these articles will help collate and clarify the already publically available information. Following each “CEO Perspective” there will be a comment section. Please use this to communicate your thoughts and questions. I hope you enjoy this new communication series and find it useful.

These “CEO Perspectives” will be a regular feature of our communication activities and may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events and use words such as “may”, “could”, “expect” and others. These statements include those regarding the hope that Galectin’s development program for GR-MD-02 will lead to the first therapy for the treatment of fatty liver disease with advanced fibrosis and cirrhosis. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements

Please look for future editions in which multiple aspects of our development programs for unmet medical needs will be addressed.

Make a Comment or Ask a Question